Search

Your search keyword '"Ogawa, Naoki"' showing total 17 results
Start Over Author "Ogawa, Naoki" Language japanese
17 results on '"Ogawa, Naoki"'

10. Biological notes and collecting method of Coleorrhyncha in New Zealand

Author

Ogawa, Naoki

Abstract

This paper reports biological notes of three coleorrhynchan species, Xenophyes rhachilophus BURCKHARDT, 2011, Oiophysa distincta WOODWARD, 1952 and O. ablusa DRAKE & SALMON, 1950, in New Zealand, and introduces an easier collecting method for the insects with a beating tray.

Published
2017

12. The First Records of Two Species of the Water Scorpions, Ranatra chinensis and Ranatra unicolor (Hemiptera: Nepidae) from Rishiri Island, Northern Hokkaido, Japan

Author

Morii, Yuta, Sato, Masahiko, and Ogawa, Naoki

Subjects
Nepidae, Ranatrinae, northernmost distribution, Rishiri Island
Abstract

Two species of the water scorpions, Ranatra chinensis and R. unicolor (Hemiptera: Nepidae) were collected for the first time on Rishiri Island, northern Hokkaido, Japan. These are also the northern most distribution records for these two species in Japan.

Published
2015

17. [Administration Period of Olanzapine as an Antiemetic Drug for Patients on FEC Therapy-A Survey].

Author

Tsurushima K, Yanagishita Y, Ogawa N, Fujii C, Yasui Y, Takeda T, Tsubaki M, Nishida S, Ishizaka T, Yamamura J, and Kamigaki S

Subjects
Antineoplastic Combined Chemotherapy Protocols adverse effects, Cyclophosphamide, Female, Humans, Nausea chemically induced, Nausea drug therapy, Nausea prevention & control, Olanzapine adverse effects, Olanzapine therapeutic use, Vomiting chemically induced, Vomiting drug therapy, Vomiting prevention & control, Antiemetics therapeutic use, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy, Breast Neoplasms etiology
Abstract

Olanzapine(OLZ)is a multi-acting receptor-targeted antipsychotic drug approved in Japan in December 2017 for the treatment of anticancer drug-induced nausea and vomiting. However, the recommended doses and administration periods of OLZ in the literature and guidelines are varied. Reports on the efficacy and safety of OLZ combined with perioperative chemotherapy for breast cancer in Japanese patients are few. Moreover, the risk of nausea and vomiting during treatment with anticancer drugs in young and women patients remains to be high. In this study, we conducted an exploratory survey on the optimal duration of OLZ administration(days 1-4: 5 mg, before sleep)during perioperative breast cancer 5-fluorouracil, epirubicin, cyclophosphamide(FEC)therapy. We found that treatment with OLZ showed efficacy in improving nausea grade and maintaining relative dose intensity. Moreover, it could be used safely without interruption due to side effects, such as weight gain, elevation in blood glucose, somnolence, and insomnia. Prophylactic antiemetic therapy with OLZ administration (days 1-4: 5 mg)prior to sleep was effective in patients having FEC therapy-induced nausea and vomiting.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results